Brain Cancer News and Research RSS Feed - Brain Cancer News and Research

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.
Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma. [More]
UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target. [More]
New MIT study implicates RNA-binding proteins in regulation of cancer

New MIT study implicates RNA-binding proteins in regulation of cancer

A new study from MIT implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation. [More]
Research finding could lead to new therapies for malignant glioma

Research finding could lead to new therapies for malignant glioma

Targeted therapies are a growing and groundbreaking field in cancer care in which drugs or other substances are designed to interfere with genes or molecules that control the growth and survival of cancer cells. Now, scientists at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have identified a novel interaction between a microRNA and a gene that could lead to new therapies for the most common and deadly form of brain tumor, malignant glioma. [More]
Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy. [More]
Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital today announced that it is actively recruiting patients to participate in a clinical trial taking place at the Hermelin Brain Tumor Center which is showing promising results in patients with brain cancer. [More]
CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the Company has received written notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold. [More]
Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. [More]
Study gives a roadmap for future brain cancer vaccines

Study gives a roadmap for future brain cancer vaccines

Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment). [More]
Researchers identify potential therapeutic target for glioblastoma

Researchers identify potential therapeutic target for glioblastoma

A multicenter team of researchers has identified an enzyme key to the survival and spread of glioblastoma cancer cells that is not present in healthy brain cells, making the enzyme a promising therapeutic target. [More]
CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs. [More]
Researchers describe new progress in treatment of brain cancer, other neurological diseases

Researchers describe new progress in treatment of brain cancer, other neurological diseases

A new technology that may assist in the treatment of brain cancer and other neurological diseases is the subject of an article in a recent issue of the journal Technology, published by World Scientific Publishing Company. [More]
Scientists devise novel way to use stem cells in fight against brain cancer

Scientists devise novel way to use stem cells in fight against brain cancer

Harvard Stem Cell Institute scientists at Massachusetts General Hospital have devised a new way to use stem cells in the fight against brain cancer. A team led by neuroscientist Khalid Shah, MS, PhD, who recently demonstrated the value of stem cells loaded with cancer-killing herpes viruses, now has a way to genetically engineer stem cells so that they can produce and secrete tumor-killing toxins. [More]
Viewpoints: Health law fails to control costs; GOP alternative 'worse than Obamacare'

Viewpoints: Health law fails to control costs; GOP alternative 'worse than Obamacare'

A major claim of ObamaCare's political salesmen is that it will reduce U.S. health spending. The heart of this claim is the Accountable Care Organization, or ACO, but already evidence is accumulating that it isn't working. [More]

Discovery could prolong life of people living with glioblastoma

Researchers at the University of Calgary's Hotchkiss Brain Institute and Southern Alberta Cancer Research Institute have made a discovery that could prolong the life of people living with glioblastoma – the most aggressive type of brain cancer. Samuel Weiss, PhD, Professor and Director of the HBI, and Research Assistant Professor Artee Luchman, PhD, and colleagues, published their work today in Clinical Cancer Research, which is leading researchers to start a human phase I/II clinical trial as early as Spring 2015. [More]
Research finding offers new insights into the cause of glioblastoma

Research finding offers new insights into the cause of glioblastoma

Researchers at the University of California, San Diego School of Medicine have identified a new fusion protein found in approximately 15 percent of secondary glioblastomas or brain tumors. The finding offers new insights into the cause of this cancer and provides a therapeutic target for personalized oncologic care. [More]
Viewpoints: Ebola myths; Sen. McCain's 'opportunistic alarmism'; Gov. Jindal on CDC's misspent resources

Viewpoints: Ebola myths; Sen. McCain's 'opportunistic alarmism'; Gov. Jindal on CDC's misspent resources

Hubris is the greatest danger in wealthy countries -; a sort of smug assumption that advanced technologies and emergency-preparedness plans guarantee that Ebola and other germs will not spread. It was hubris that left Toronto's top hospitals battling SARS in 2003, long after the virus was conquered in poorer Vietnam. It was hubris that led the World Health Assembly in 2013 to cut the WHO's outbreak-response budget in favor of more programs to treat cancer and heart disease. [More]
Viewpoints: Walmart and Obamacare; negative views continue of health law; Ebola preparedness

Viewpoints: Walmart and Obamacare; negative views continue of health law; Ebola preparedness

Walmart announced today that as of the beginning of next year it will be dropping health insurance for 30,000 employees who work less than 30 hours per week. Many liberals will react to the news by saying that it's just a profit-hungry corporation once again screwing over its employees. Conservatives are likely to say that this just shows what a mess Obamacare has created and why it should be repealed (Paul Waldman, 10/8). [More]
CUMC researchers use innovative algorithm to find driving force behind aggressive form of glioblastoma

CUMC researchers use innovative algorithm to find driving force behind aggressive form of glioblastoma

Using an innovative algorithm that analyzes gene regulatory and signaling networks, Columbia University Medical Center researchers have found that loss of a gene called KLHL9 is the driving force behind the most aggressive form of glioblastoma, the most common form of brain cancer. [More]
VAL-083 drug compound shows promise against non-small cell lung cancer

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai. [More]